Avsar.

Healthcare · Pharmaceuticals

Zydus Lifesciences Ltd (ZYDUSLIFE)

₹1,108.70

Mkt cap
₹1.11L Cr
P/E ratio
20.40
P/B
4.12
Div yield
0.09%
ROE
21.20%
ROCE
21.10%
EPS (TTM)
₹54.35
Book value
₹269
52W range
861–1,159
Sector
Healthcare

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

NSE ZYDUSLIFEBSE 532321www.zyduscadila.com
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−4.34% from high
₹1,109
₹861+28.83% from low₹1,159
Current
₹1,108.70
Prev close
₹1,111.80
Day
−0.28%
Price performance
1D
−0.28%
1W
−3.51%
1M
+0.66%
3M
+19.55%
6M
+26.94%
1Y
+12.82%
YTD
+20.92%

Financials

F
Revenue, profit & margin
P/E ratio
20.4×
ZYDUSLIFE is 40% below the sector median of 33.9×
ZYDUSLIFE20.4×
Sector median33.9×
 Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Trend
Sales5,0115,1404,3694,5055,5346,2085,2375,2696,5286,5746,1236,8647,587
Expenses3,7553,6343,2233,4033,9034,1243,7763,8824,4024,4854,1075,0485,033
Operating Profit1,2561,5051,1461,1021,6302,0841,4611,3882,1262,0882,0161,8162,554
OPM %25%29%26%24%29%34%28%26%33%32%33%26%34%
Other Income-566215360160636857-1391557526-263
Interest2818920353225327785101130123
Depreciation179180184195205215234229238238302360508
Profit before tax4841,3281,0069471,5501,9001,2711,1841,6721,9211,6871,3531,660
Tax %28%16%22%23%21%23%29%15%25%23%27%29%19%
Net Profit3581,1348037901,2461,4829201,0261,2441,5211,2391,0231,341
EPS in Rs2.9310.747.917.8011.7514.119.0610.1711.6414.5812.5110.3612.65
Raw PDF

Earnings

EResults dates & reactions
Next results
11 Aug '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.35% · closed higher next day 31 of last 61
 Q1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26
Broadcast11 Aug '237 Nov '23◦9 Feb '24◦17 May '24◦9 Aug '24◦12 Nov '24◦5 Feb '25◦20 May '25◦12 Aug '256 Nov '259 Feb '2619 May '26
Earnings day−1.05%+4.67%+6.41%+5.00%−3.88%+1.47%+3.19%+0.72%+0.01%−3.60%+3.97%+2.80%
+1 day−2.46%+2.54%+6.55%+3.51%−9.64%+0.81%+1.76%+2.28%+3.46%−2.84%−0.10%+5.02%
+5 days−0.72%+5.78%+12.73%+0.68%−8.32%−0.07%−3.50%+4.79%+2.90%−2.84%+2.51%+8.87%
+15 days−5.68%+7.10%+17.54%+3.30%−14.37%+4.77%−10.28%+10.81%+5.90%−3.55%+2.11%+10.82%
+30 days−9.09%+13.84%+24.18%+2.21%−19.17%+0.76%−5.46%+12.69%+6.67%−5.97%−0.20%+10.97%
FilingXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRL

Corporate actions

CLast 6 months
KindValueEx-dateRecord
dividend
Dividend - Re 1 Per Share
—24 Jul '2624 Jul '26
other
Buy Back
—29 May '2629 May '26

Shareholding

Sas of Jun 2026
75.02%Promoter
Promoters75.02%0.02
FIIs6.89%0.06
DIIs11.27%0.07
Public6.83%0.03
Government0.00%
Ownership trend

Peers

P7 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,941.1037.484,65,7230.82%2,710+13.58%14,612+12.76%20.53%
Divi's Lab.₹7,248.5073.361,92,4250.41%751+13.44%2,831+9.52%21.97%
Torrent Pharma.₹4,961.5086.101,88,6970.77%364−20.58%4,197+41.84%15.19%
Cipla₹1,410.6031.841,13,9550.92%786−39.19%7,119+2.33%15.49%
Zydus Lifesci.₹1,108.7020.381,10,5930.09%1,341+21.92%7,587+16.22%21.14%
Lupin₹2,370.5019.061,08,4010.76%1,469+101.49%7,475+31.89%29.93%
Mankind Pharma₹2,507.2051.441,03,5590.04%559+34.23%3,443+11.81%13.53%
Median: 157 Co.₹432.0533.931,9700.10%15+28.10%176+17.66%15.10%

Filings

D
Annual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts82
TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025PPTMay 2025TranscriptMar 2025PPTMar 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024
Credit ratings6
Rating update 9 Sep 2025crisilRating update 18 Mar 2025crisilRating update 27 Dec 2024crisilRating update 2 Jan 2024crisilRating update 9 Jan 2023crisilRating update 20 Jan 2022crisil
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 1d - Zydus received approval for Phase III Desidustat trial in sickle cell disease with ICMR.Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On June 30, 2026. 20 Jul - Board meets August 11, 2026 to approve Q1 FY2027 unaudited results; trading window closed till August 13.Reply To The Clarification Sought From The Company 15 Jul - Zydus denies material impact from Delhi High Court’s temporary restriction on IkraTM supply.Clarification sought from Zydus Lifesciences Ltd 14 Jul - Exchange has sought Clarification from Zydus Lifesciences Ltd with reference to the media report appearing on https://www.ndtvprofit.com dated July 14, 2026, (Link: https://www.ndtvprofit.com/business/delhi-high-court-temporarily-restricts-supply-of-zydus-cancer-drug-ikra-in-abbvie-patent-dispute-11764992) ....Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Jul - The newspaper cutting dated July 11, 2026, with regard to Notice of 31st Annual General Meeting of the Company published in the Financial Express.